Olink Services

ISB teams up with Olink® to advance your research.

ISB, together with Olink, brings you the most advanced products and services for protein biomarker discovery.

Get a Quote

Our expertise makes us an ideal partner to advance your proteomic research.

ISB is a leader in biomedical scientific research working at the cutting edge of advancements in human health and personalized medicine. We have more than a decade of experience using Olink data for biomarker discovery and validation to study disease areas like cardiovascular disease, cancer and neurodegenerative disease. We have also done pioneering research on healthy populations.

Services Offered

Olink® Explore

The Olink Explore is a high-multiplex, high-throughput protein biomarker platform that uses Proximity Extension Assay (PEA) technology coupled with an innovative new readout methodology based on Next Generation Sequencing (NGS) using Illumina’s NextSeq 2000. Explore can quantify 384 to 3,072 proteins in a single run.

Learn More

Services Offered

Olink® Target 96

Olink Target 96 panels are able to achieve a high level of multiplexing while maintaining exceptional data quality thanks to Olink’s proprietary PEA technology with a qPCR-based readout using Fluidigm’s Biomark HD. Each biomarker is addressed by a matched pair of antibodies, coupled to unique, partially complementary oligonucleotides, and measured by quantitative real-time PCR. Target 96 is available for more than a dozen panels, including neurology, inflammation, cardiovascular disease, and oncology

Learn More

What’s Next

Augment your plate design with additional pooled technical control samples and bridge your samples to our growing in-house population of healthy control individuals. This enables flexible in silico designs that preserve the continuity of data over time and allow for synthetic cohort matching.

ISB has extensive experience in multi-omic research on healthy individuals from wellness cohorts as well as specific disease states. We are proud to have contributed part of our unique dataset of N=300 healthy control individuals to be integrated into Olink’s newest line of 3KN products and the accompanying Olink® Insight software.

Learn more

High-Impact ISB Publications Utilizing Olink Datasets

• Su Y, Chen D, Yuan D, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183(6):1479–1495.e20. doi:10.1016/j.cell.2020.10.037.
  Price ND, Magis AT, Earls JC, et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat Biotechnol. 2017;35(8):747-756. doi:10.1038/nbt.3870.
• Magis AT, Rappaport N, Conomos MP, et al. Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis. Sci Rep. 2020;10(1):16275-16276. doi:10.1038/s41598-020-73451-z.
• Grasberger H, Magis AT, Sheng E, et al. DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk. J Clin Invest. 2021;131(9). doi:10.1172/JCI141676.
• Kornilov SA, Lucas I, Jade K, Dai CL, Lovejoy JC, Magis AT. Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. Crit Care. 2020;24(1):452-453. doi:10.1186/s13054-020-03141-9.
• Earls JC, Rappaport N, Heath L, et al. Multi-Omic Biological Age Estimation and Its Correlation With Wellness and Disease Phenotypes: A Longitudinal Study of 3,558 Individuals. Le Couteur D, ed. J Gerontol A Biol Sci Med Sci. 2019;74(Supplement_1):S52-S60. doi:10.1093/gerona/glz220.
• Wilmanski T., Rappaport N., Earls JC, Magist AT, Manor O, Lovejoy J, Omenn GS, Hood L, Gibbons SM, Price ND. Blood metabolome predicts gut microbiome a-diversity in humans. Nat Biotech. 2019;37. 1217-1228. doi:10.1038/s41587-019-0233-9.
• Wainberg M., Magis AT, Earls JC, Lovejoy JC, Sinnott-Armstrong N., Omenn GS, Hood L., Price ND. Multiomic blood correlates of genetic risk identify presymptomatic disease alterations. PNAS 2020;117(35). 21813-21820. doi:10.1073/pnas.2001429117.
• Zheng, H., Rao, A.M., Dermadi, D., Toh, J., Jones, L.M., Donato, M., Liu, Y., Su, Y., Dai, C., Kornilov, S., Karagiannis, M., Marantos, T., Hasin, Y., He, Y., Giamarellos-Bourboulis, E.J., Heath, J., Khatri, P. Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity irrespective of virus. Immunity 2021; 54, 1-15. doi:10.1016/j.immuni.2021.03.002.
• Su Y., Yuan D., Chen DG, Ng RH, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185. 881-895  doi:10.1016/j.cell.2022.01.014.